Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. Patients with advanced malignancies were eligible. There were two treatment cycles; ...
Leipzig and Berlin, Germany - In the setting of acute ST-elevation MI (STEMI) treated with PCI, giving the initial bolus of abciximab (ReoPro, Eli Lilly/Centocor) by the intracoronary (IC) route, ...
Asthma is an inflammatory disease typified by airway hyperreactivity and obstruction-producing airway resistance with a reduction in air flow. [1] The mainstay of treatment of acute asthma in children ...
ORLANDO, FL—Intracoronary abciximab does not reduce rates of death or myocardial infarction (MI) compared to standard intravenous (IV) administration of the glycoprotein IIb/IIIa inhibitor in patients ...
The glycoprotein IIb/IIIa inhibitor abciximab given as an intracoronary rather than intravenous (IV) bolus in patients undergoing primary percutaneous coronary intervention (PCI) may improve ...
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study Various pharmacologic strategies have been ...
At a recent meeting of the AAMI Healthcare Technology Safety Institute, researchers from the University of Toronto released a report that provides nine specific recommendations to reduce the risks ...
People aged 16 or over at high risk of severe illness or death from sepsis in acute hospital settings have an intravenous fluid bolus within 1 hour of risk being identified, unless contraindicated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback